Article
Pharmacology & Pharmacy
Steven S. Bae, Mohit Sodhi, David Maberley, Abbas Kezouh, Mahyar Etminan
Summary: There is an increased risk of maculopathy with the use of pentosan polysulfate sodium (PPS), especially with longer duration of use.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2022)
Article
Orthopedics
Ravi Krishnan, Melanie Duiker, Penny A. Rudd, Donna Skerrett, James G. D. Pollard, Carolyn Siddel, Rifat Rifat, Jennifer H. K. Ng, Peter Georgius, Lara J. Hererro, Paul Griffin
Summary: The study evaluated the safety and efficacy of pentosan polysulfate sodium (PPS) in subjects with Ross River virus (RRV)-induced arthralgia. Findings showed that PPS was well tolerated in both treatment and placebo groups, and demonstrated significant improvements in joint function and quality of life.
BMC MUSCULOSKELETAL DISORDERS
(2021)
Article
Ophthalmology
Gerald McGwin, Paul MacLennan, Cynthia Owsley
Summary: Case series have identified a macular condition hypothesized to be associated with the use of pentosan polysulfate sodium (PPS). Observational studies seeking to quantify this association have yielded equivocal results. The results suggest that PPS use is associated with an increased risk of maculopathy, and ruling out prevalent retinal abnormalities before initiating PPS treatment would strengthen the current body of literature.
JAMA OPHTHALMOLOGY
(2022)
Review
Chemistry, Medicinal
Margaret M. Smith, James Melrose
Summary: This review outlines the potential of pentosan polysulfate (PPS) as a therapeutic agent in various disease processes. PPS exhibits tissue-protective properties and has been used in the treatment of interstitial cystitis, painful bowel disease, cartilage-related conditions, and tissue engineering. It regulates complement activation, coagulation, and fibrinolysis, promotes hyaluronan synthesis, inhibits nerve growth factor production, removes fatty compounds, and regulates cytokine production. PPS also acts as an anti-tumor agent and stimulates the proliferation and differentiation of stem cells. Overall, PPS is a multifunctional molecule with therapeutic potential for a diverse range of diseases.
Review
Ophthalmology
Aaron Lindeke-Myers, Adam M. Hanif, Nieraj Jain
Summary: Long-term use of pentosan polysulfate sodium (PPS) can lead to a vision-threatening macular condition, with symptoms such as prolonged dark adaptation and difficulty reading. Fundus examination often shows macular pigment clumps, and fundus autofluorescence imaging is most clear in depicting this condition.
SURVEY OF OPHTHALMOLOGY
(2022)
Article
Urology & Nephrology
Andreas Wiedemann
Summary: Pentosan polysulfate sodium is considered to be an effective drug for interstitial cystitis/bladder pain syndrome, despite some side effects and controversies. It should still be considered as part of current and future therapy, even though undersupply issues in Germany may worsen with ongoing litigation.
Article
Urology & Nephrology
George Kasyan, Yury Kupriyanov, Alexander Karasev, Kirill Baibarin, Dmitry Pushkar
Summary: The study evaluated the use of pentosan polysulfate sodium in the complex treatment of bladder pain syndrome/interstitial cystitis. Results showed that pentosan therapy was more effective than placebo with comparable safety, recommending its inclusion in the comprehensive treatment plan for patients.
CENTRAL EUROPEAN JOURNAL OF UROLOGY
(2021)
Article
Urology & Nephrology
Jan Alberto Paredes Mogica, Elise J. B. De
Summary: Most of the 14 papers identified reported on the development of macular disease after chronic exposure to pentosan polysulfate sodium. No randomized controlled trials have been conducted to date, and data was insufficient for a meta-analysis. However, patients with interstitial cystitis were more likely to be diagnosed with maculopathy after years of medication use.
Article
Oncology
Rachel Hatch, Craig W. Freyer, Alison Carulli, Selina M. Luger, Mary E. Martin, Shannon R. McCurdy, David L. Porter, Alison W. Loren
Summary: This report retrospectively analyzed 6 cases of hemorrhagic cystitis following an allogeneic hematopoietic cell transplant treated with pentosan polysulfate, and found that it may assist with symptom resolution. Further studies are needed to confirm its treatment effect.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
(2022)
Article
Ophthalmology
Neil S. Kalbag, Nenita Maganti, Alice T. Lyon, Rukhsana G. Mirza
Summary: The study investigated the prevalence of retinal pathology in patients with a history of exposure to pentosan polysulfate sodium (PPS) and identified a novel drug-induced maculopathy associated with PPS use. This maculopathy has distinct clinical features that can be accurately identified with multimodal imaging.
CLINICAL OPHTHALMOLOGY
(2021)
Article
Ophthalmology
Ogul E. Uner, Megha K. Shah, Nieraj Jain
Summary: A survey conducted among individuals with interstitial cystitis taking pentosan polysulfate (PPS) revealed that those with the highest exposure to PPS were more likely to experience visual difficulties and have a diagnosis of macular disease. Further research on objective measures of visual function in PPS users is recommended.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
(2021)
Article
Ophthalmology
Andrew C. Dieu, Samuel A. Whittier, Amitha Domalpally, Jeong W. Pak, Rick P. Voland, Kelly M. Boyd, Justin L. Gottlieb, Gordon S. Crabtree, Dobie L. Giles, Sarah E. McAchran, Mihai Mititelu
Summary: There is growing evidence of a direct association between PPS therapy and macular changes. This study examined the impact of PPS therapy on vision using standardized tests and imaging. The findings suggest a wider range of structural abnormalities in PPS users, particularly affecting the retina beyond the arcades.
OPHTHALMOLOGY RETINA
(2022)
Review
Obstetrics & Gynecology
Rajesh Taneja
Summary: Oral pentosan polysulfate (PPS) has been used in the treatment of bladder pain syndrome/interstitial cystitis for nearly 35 years, with most studies showing clear benefits for patients. While there are some conflicting results in recent research, overall, PPS remains a useful pharmacological agent for treating BPS/IC.
INTERNATIONAL UROGYNECOLOGY JOURNAL
(2021)
Review
Urology & Nephrology
Bagrat Grigoryan, George Kasyan, Laura Pivazyan, Dmitry Pushkar
Summary: The study evaluates the efficacy and safety of pentosan polysulfate (PPS) in patients with BPS/IC through systematic review and meta-analysis. The results showed that oral PPS treatment had a statistically significant effect over placebo on the subjective improvement of patients with BPS/IC, but no significant difference was found between PPS and other treatment options. Additionally, intravesical PPS regimen did not have a significant impact on response rates, with no severe side effects reported in included studies.
THERAPEUTIC ADVANCES IN UROLOGY
(2022)
Article
Obstetrics & Gynecology
Allison Lardieri, Karen Konkel, Lynda McCulley, S. Christopher Jones, David Moeny, Christine Nguyen, Catherine Sewell, Wiley Chambers, Adebola Ajao
Summary: The data reviewed from the FDA Adverse Event Reporting System and published case reports and observational studies do not definitively establish a causal link between the use of pentosan polysulfate sodium and retinal pigmentary changes. However, there are several elements that suggest a potential association. Urogynecologists prescribing pentosan should be aware of this possible association and monitor the eye health of pentosan users attentively.
INTERNATIONAL UROGYNECOLOGY JOURNAL
(2021)
